A “double chin” (submittal fullness) affects a large number of men and women who have found themselves in the midst of dealing with the process of aging. It’s a challenging time, that’s for sure. Excess fat in the chin area can be the result of genetics, weight gain, or aging. However it gets there, it is unattractive and self-esteem deflating. If you would love to reduce the appearance of your double chin, you’re not alone. Loving their neck is something many men and women struggle with, but Dr. Price offers a revolutionary, new answer – KYBELLA®, the first and only FDA approved non-surgical treatment for improving the appearance of moderate to severe fat below the chin. Read on to learn more.
- KYBELLA® is an injectable treatment whose active ingredient is deoxycholic acid, a naturally-occurring molecule in the body that aids in the absorption and breakdown of dietary fat.
- When it is injected beneath the chin, KYBELLA® causes the destruction of fat cells, and once these cells are destroyed, they cannot store or accumulate additional fat.
- KYBELLA® is available as treatments, and because everyone is unique, we will help you decide how many treatments you will need to achieve your desired aesthetic results.
KYBELLA® can cause serious side effects, including nerve injury to the jaw, or trouble swallowing. The most common side effects of KYBELLA® are bruising, pain, redness, swelling and numbness, as well as areas of possible hardness in the treatment area.
Before you schedule a KYBELLA® treatment, be sure to tell Dr. Price about any medical conditions you have; the prescription and over-the-counter medicines you are taking; if you have had or plan to have surgery on your face, chin or neck, or if you have had cosmetic treatments to these areas. Let him know if you have trouble swallowing, bleeding problems, are breast-feeding, pregnant or planning to become pregnant, or if you are taking a blood-thinner.
To learn more about this new injectable treatment, call to schedule an appointment, today: (203) 453-6635.
No comments yet.